Effect of raloxifene on serum triglycerides in women with a history of hypertriglyceridemia while on oral estrogen therapy

Diabetes Care

Volumn 28, Issue 7, 2005, Pages 1555-1561

  Carr, Molly C ^a,d   Knopp, Robert H ^b   Brunzell, John D ^b   Wheeler, Barbara S ^b   Zhu, Xiaodong ^b   Lakshmanan, Mark ^c   Rosen, Amy S ^c   Anderson, Pamela W ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ESTROGEN; FIBRIC ACID DERIVATIVE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIVER TRIACYLGLYCEROL LIPASE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TRIACYLGLYCEROL;

ADULT; AGED; ANAMNESIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG INDICATION; DRUG MONITORING; DRUG WITHDRAWAL; ENZYME ACTIVITY; ESTROGEN THERAPY; FEMALE; GLUCOSE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; HYPERTRIGLYCERIDEMIA; PATIENT COMPLIANCE; POSTMENOPAUSE;

EID: 21544472890     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.28.7.1555     Document Type: Article

References (45)

1. Delmas PD, Bjarnason NH, Millak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C: Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641-1647, 1997
2. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli EV, Lips P, Cummings SR, Multiple Outcomes of Raloxifene Evaluation Investigators: Reduction of vertebral fracture risk in post-menopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282:637-645, 1999
3. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, Shah AS, Anderson PW: Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 279: 1445-1451, 1998
4. Davies GC, Huster WJ, Shen W, Mitlak B, Plouffe L Jr, Shah A, Cohen FJ: Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women. Menopause 6: 188-195, 1999
5. Cohen FJ, Watts S, Shah A, Akers R, Plouffe L Jr: Uterine effects of 3-year raloxifene therapy in postmenopausal women younger than age 60. Obstet Gynecol 95: 104-110, 2000
6. Nickelsen T, Creatsas G, Rechberger T, Depypere H, Erenus M, Quail D, Arndt T, Bonnar J: Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: results from the Euralox 1 study. Climacteric 4:320-331, 2001
7. Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, Rautaharju P, Harper KD: Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 287:847-857, 2002
8. Barrett-Connor E, Ensrud KE, Harper K, Mason TM, Sashegyi A, Krueger KA, Anderson PW: Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes. Clin Ther 25:919-930, 2003
9. Writing Group for the PEPI Trial: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial [erratum in JAMA 274:1676, 1995] [see comments]. JAMA 273:199-208, 1995
10. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E, Heart and Estrogen/progestin Replacement Study (HERS) Research Group: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women [see comments]. JAMA 280:605-613, 1998
11. Adami S, Rossini M, Zamberlan N, Bertoldo F, Dorizzi R, Lo Cascio V: Long-term effects of transdermal and oral estrogens on serum lipids and lipoproteins in postmenopausal women. Maturitas 17:191-196, 1993
12. Hanggi W, Lippuner K, Riesen W, Jaeger P, Birkhauser MH: Long-term influence of different postmenopausal hormone replacement regimens on serum lipids and lipoprotein(a): a randomised study. Br J Obstet Gynaecol 104:708-717, 1997
13. Stone NJ: Estrogen-induced pancreatitis: a caveat worth remembering. J Lab Clin Med 123:18-19, 1994
14. Glueck CJ, Lang J, Hamer T, Tracy T: Severe hypertriglyceridemia and pancreatitis when estrogen replacement therapy is given to hypertriglyceridemic women. J Lab Clin Med 123:59-64, 1994
15. Agarwal M, Lunt H, Scott R: Hormone replacement therapy, diabetes and pancreatitis secondary to hypertriglyceridaemia. N Z Med J 110:426, 1997
16. Lufkin EG, Ory SJ: Relative value of transdermal and oral estrogen therapy in various clinical situations. Mayo Clin Proc 69: 131-135, 1994
17. Sanada M, Tsuda M, Kodama I, Sakashita T, Nakagawa H, Ohama K: Substitution of transdermal estradiol during oral estrogen-progestin therapy in postmenopausal women: effects on hypertriglyceridemia. Menopause 11:331-336, 2004
18. Peverill RE: Hormone therapy and venous thromboembolism. Best Pract Res Clin Endocrinol Metab 17:149-164, 2003
19. Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW, Stepan JJ, Powles TJ, Morrow M, Costa A, Silfen SL, Walls EL, Schmitt H, Muchmore DB, Jordan VC, Ste-Marie LG: Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation [erratum in Breast Cancer Res Treat 67: 191, 2001]. Breast Cancer Res Treat 65: 125-134, 2001
20. Warnick GR: Enzymatic methods for quantification of lipoprotein lipids. Methods. Enzymol 129:101-123, 1986
21. Warnick GR, Benderson J, Albers JJ: Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-densitylipoprotein cholesterol. Clin Chem 28: 1379-1388, 1982
22. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502, 1972
23. Marcovina SM, Albers JJ, Gabel B, Koschinsky ML, Gaur VP: Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem 41:246-255, 1995
24. Zhu X, Bonet B, Gillenwater H, Knopp RH: Opposing effects of estrogen and pro gestins on LDL oxidation and vascular wall cytotoxicity: implications for atherogenesis. Proc Soc Exp Biol Med 222:214-221, 1999
25. Iverius P, Brunzell J: Human adipose tissue lipoprotein lipase: changes with feeding in relation to postheparin plasma enzyme. Am J Physiol 249:326-334, 1985
26. de Valk-de Roo GW, Stehouwer CD, Meijer P, Mijatovic V, Kluft C, Kenemans P, Cohen F, Watts S, Netelenbos C: Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy post-menopausal women: a 2-year, placebo-controlled study. Arterioscler Thromb Vasc Biol 19:2993-3000, 1999
27. Tsai KS, Yen ML, Pan HA, Wu MH, Cheng WC, Hsu SH, Yen BL, Huang KE: Raloxifene versus continuous combined estrogen/progestin therapy: densitometric and biochemical effects in healthy postmenopausal Taiwanese women. Osteoporos Int 12:1020-1025, 2001
28. De Leo V, la Marca A, Morgante G, Lanzetta D, Setacci C, Petraglia F: Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women. Am J Obstet Gynecol 184:350-353, 2001
29. Cagnacci A, Paoletti AM, Zanni A, Arangino S, Ibba G, Orru M, Melis GB, Volpe A: Raloxifene does not modify insulin sensitivity and glucose metabolism in postmenopausal women. J Clin Endocrinol Metab 87:4117-4121, 2002
30. Morii H, Ohashi Y, Taketani Y, Fukunaga M, Nakamura T, Itabashi A, Sarkar S, Harper K: Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial. Osteoporos Int 14:793-800, 2003
31. Lasco A, Gaudio A, Morabito N, Previti M, Mileto A, Frisina N, Cucinotta D: Effects of a long-term treatment with raloxifene on insulin sensitivity in postmenopausal women. Diabetologia 47:571-574, 2004
32. Lamarche B, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Despres JP: Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 17:1098-1105, 1997
33. Mosca L, Harper K, Sarkar S, O'Gorman J, Anderson PW, Cox DA, Barrett-Connor E: Effect of raloxifene on serum triglycerides in postmenopausal women: influence of predisposing factors for hypertriglyceridemia. Clin Ther 23:1552-1565, 2001
34. Tikkanen MJ, Nikkila EA, Kuusi T, Sipinen SU: High density lipoprotein-2 and hepatic lipase: reciprocal changes produced by estrogen and norgestrel. J Clin Endocrinol Metab 54:1113-1117, 1982
35. Zambon A, Hokanson JE, Brown BG, Brunzell JD: Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation 99:1959-1964, 1999
36. Kuusi T, Saarinen P, Nikkila EA: Evidence for the role of hepatic endothelial lipase in the metabolism of plasma high density lipoprotein2 in man. Atherosclerosis 36: 589-593, 1980
37. Salonen JT, Salonen R, Seppanen K, Rauramaa R, Tuomilehto J: HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction: a prospective population study in eastern Finnish men. Circulation 84:129-139, 1991
38. Zuckerman SH, Bryan N: Inhibition of LDL oxidation and myeloperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene (LY139481 HCL). Atherosclerosis 126:65-75, 1996
39. Mosca L, Barrett-Connor E, Wenger NK, Collins P, Grady D, Kornitzer M, Moscarelli E, Paul S, Wright TJ, Helterbrand JD, Anderson PW: Design and methods of the Raloxifene Use for The Heart (RUTH) study. Am J Cardiol 88:392-395, 2001
40. Wenger NK, Barrett-Connor E, Collins P, Grady D, Kornitzer M, Mosca L, Sashegyi A, Baygani SK, Anderson PW, Moscarelli E: Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) trial. Am J Cardiol 90:1204-1210, 2002
41. Molitch ME, Oill P, Odell WD: Massive hyperlipidemia during estrogen therapy. J Am Med Assoc 227:522-525, 1974
42. Chait A, Brunzell JD: Severe hypertriglyceridemia: role of familial and acquired disorders. Metabolism 32:209-214, 1983
43. Henkin Y, Como JA, Oberman A: Secondary dyslipidemia: inadvertent effects of drugs in clinical practice. JAMA 267:961-968, 1992
44. Mantel-Teeuwisse AK, Kloosterman JM, Maitland-van der Zee AH, Klungel OH, Porsius AJ, de Boer A: Drug-induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels. Drug Saf 24:443-456, 2001
45. Goldenberg NM, Wang P, Glueck CJ: An observational study of severe hypertriglyceridemia, hypertriglyceridemic acute pancreatitis, and failure of triglyceride-lowering therapy when estrogens are given to women with and without familial hypertriglyceridemia. Clin Chim Acta 332: 11-19, 2003